, /PRNewswire/ -- (NYSE: ), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio. The enhancements strengthen Labcorp's leadership as a premier, single-source partner for biopharmaceutical companies in advancing cancer research and patient care both in and globally. "Labcorp's portfolio expansion enhances our integrated service offerings and empowers our partners with the support and solutions they need to advance their therapeutic development programs," said Shakti Ramkissoon, M.
D., Ph.D.
, MBA, vice president, medical lead for oncology at Labcorp. "Combined, this can make a lasting difference in patients' lives and health outcomes." Labcorp Tissue Complete, which is powered by the FDA-cleared and CE-marked PGDx elioTM tissue complete assay, is a comprehensive genomic profiling (CGP) service for research and investigational use.
The offering leverages the global reach of Labcorp's central laboratories, standardizing multi-site biomarker-directed patient testing. Labcorp's standardized approach reduces variability, which can result from different chemistries, workflows and data analysis pipelines. This expansion will extend availability of the service through owned laboratories in and to support research and investigational use in global clinical trials, streamlining access for patients to oncology clinical trials, broadening the patient population, and helping improve logis.
